Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Long-term follow-up, crossover, and rechallenge with pembrolizumab in the phase III KEYNOTE-716 study
European Journal of Cancer · 2025-05 · 220 · 115381
DOI: 10.1016/j.ejca.2025.115381 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Cancer, 2025-05. Verfasst von Jason J Luke und 20 weiteren Autor:innen. Beteiligte Einrichtung: UPMC Hillman Cancer Center and University of Pittsburgh, Pittsburgh, PA, USA. Electronic address: lukejj@upmc.edu. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological, Melanoma, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- UPMC Hillman Cancer Center and University of Pittsburgh, Pittsburgh, PA, USA. Electronic address: lukejj@upmc.edu.
- Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy.
- Fiona Stanley Hospital and Edith Cowan University, Perth, WA, Australia.
- Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
- IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Zitieren
APA
Luke, J. J., Ascierto, P. A., Khattak, M. A., Rutkowski, P., Del Vecchio, M., Spagnolo, F., Mackiewicz, J., Merino, L. C., Chiarion-Sileni, V., Kirkwood, J. M., Robert, C., Schadendorf, D., de Galitiis, F., Carlino, M. S., Dummer, R., Mohr, P., Odeleye-Ajakaye, A., Fukunaga-Kalabis, M., Krepler, C., …, & Long, G. V. (2025). Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Long-term follow-up, crossover, and rechallenge with pembrolizumab in the phase III KEYNOTE-716 study. European Journal of Cancer, 220, 115381. https://doi.org/10.1016/j.ejca.2025.115381
Vancouver
Luke JJ, Ascierto PA, Khattak MA, Rutkowski P, Del Vecchio M, Spagnolo F, et al. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Long-term follow-up, crossover, and rechallenge with pembrolizumab in the phase III KEYNOTE-716 study. European Journal of Cancer. 2025;220:115381. doi:10.1016/j.ejca.2025.115381
BibTeX
@article{Luke2025,
author = {Luke, Jason J and Ascierto, Paolo A and Khattak, Muhammad A and Rutkowski, Piotr and Del Vecchio, Michele and Spagnolo, Francesco and Mackiewicz, Jacek and Merino, Luis de la Cruz and Chiarion-Sileni, Vanna and Kirkwood, John M and Robert, Caroline and Schadendorf, Dirk and de Galitiis, Federica and Carlino, Matteo S and Dummer, Reinhard and Mohr, Peter and Odeleye-Ajakaye, Amos and Fukunaga-Kalabis, Mizuho and Krepler, Clemens and Eggermont, Alexander M M and Long, Georgina V},
title = {Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Long-term follow-up, crossover, and rechallenge with pembrolizumab in the phase III KEYNOTE-716 study},
journal = {European Journal of Cancer},
year = {2025},
volume = {220},
pages = {115381},
doi = {10.1016/j.ejca.2025.115381}
}
EUVIMED